23 research outputs found
Supplement: "Localization and broadband follow-up of the gravitational-wave transient GW150914" (2016, ApJL, 826, L13)
This Supplement provides supporting material for Abbott et al. (2016a). We briefly summarize past electromagnetic (EM) follow-up efforts as well as the organization and policy of the current EM follow-up program. We compare the four probability sky maps produced for the gravitational-wave transient GW150914, and provide additional details of the EM follow-up observations that were performed in the different bands
Localization and broadband follow-up of the gravitational-wave transient GW150914
A gravitational-wave (GW) transient was identified in data recorded by the Advanced Laser Interferometer Gravitational-wave Observatory (LIGO) detectors on 2015 September 14. The event, initially designated G184098 and later given the name GW150914, is described in detail elsewhere. By prior arrangement, preliminary estimates of the time, significance, and sky location of the event were shared with 63 teams of observers covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths with ground- and space-based facilities. In this Letter we describe the low-latency analysis of the GW data and present the sky localization of the first observed compact binary merger. We summarize the follow-up observations reported by 25 teams via private Gamma-ray Coordinates Network circulars, giving an overview of the participating facilities, the GW sky localization coverage, the timeline, and depth of the observations. As this event turned out to be a binary black hole merger, there is little expectation of a detectable electromagnetic (EM) signature. Nevertheless, this first broadband campaign to search for a counterpart of an Advanced LIGO source represents a milestone and highlights the broad capabilities of the transient astronomy community and the observing strategies that have been developed to pursue neutron star binary merger events. Detailed investigations of the EM data and results of the EM follow-up campaign are being disseminated in papers by the individual teams
Localization and Broadband Follow-up of the Gravitational-wave Transient GW150914
A gravitational-wave (GW) transient was identified in data recorded by
the Advanced Laser Interferometer Gravitational-wave Observatory (LIGO)
detectors on 2015 September 14. The event, initially designated G184098
and later given the name GW150914, is described in detail elsewhere. By
prior arrangement, preliminary estimates of the time, significance, and
sky location of the event were shared with 63 teams of observers
covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths
with ground- and space-based facilities. In this Letter we describe the
low-latency analysis of the GW data and present the sky localization of
the first observed compact binary merger. We summarize the follow-up
observations reported by 25 teams via private Gamma-ray Coordinates
Network circulars, giving an overview of the participating facilities,
the GW sky localization coverage, the timeline, and depth of the
observations. As this event turned out to be a binary black hole merger,
there is little expectation of a detectable electromagnetic (EM)
signature. Nevertheless, this first broadband campaign to search for a
counterpart of an Advanced LIGO source represents a milestone and
highlights the broad capabilities of the transient astronomy community
and the observing strategies that have been developed to pursue neutron
star binary merger events. Detailed investigations of the EM data and
results of the EM follow-up campaign are being disseminated in papers by
the individual teams.
</p
Identifying patients with a history of ovarian cancer for referral for genetic counselling : non-randomised comparison of two case-finding strategies in primary care
BACKGROUND: Recent guidelines recommend genetic counselling and DNA testing (GCT) for patients with ovarian cancer and survivors of ovarian cancer. Finding survivors of ovarian cancer is challenging. Detecting and referring them for GCT via primary care, to allow proper screening recommendations for patients and their family, may be a solution. AIM: To compare the effectiveness and acceptance of two pilot strategies directed at case finding women with a history of ovarian cancer for referral for GCT by their GP. DESIGN AND SETTING: Non-randomised comparison of the pilot implementation of two case-finding strategies for women with a history of ovarian cancer in Dutch primary care from May 2016 to April 2017. METHOD: Strategy A (unsupported) asked GPs to identify and refer eligible patients with a history of ovarian cancer. Strategy B (ICT-supported) provided GPs with information and communication technology (ICT) support to identify patients with a history of ovarian cancer electronically. The effectiveness of each strategy was assessed as the proportion of patients who were approached, referred for GCT, and seen by the clinical geneticist. Acceptance of each strategy was assessed by the intervention uptake of GP practices and GP and patient questionnaires. RESULTS: Nineteen out of 30 (63%) patients identified with a history of ovarian cancer were deemed eligible for referral for strategy A, and 39 out of 94 (41%) for strategy B. For each strategy, eight patients were referred and five (63%) were seen for GCT. The intervention uptake by GP practices was 31% (11 out of 36) for strategy A and 46% (21 out of 46) for strategy B. GPs considered 'relevance' and 'workability' as facilitators across both strategies whereas, for strategy B, technical barriers hindered implementation. CONCLUSION: The effectiveness and acceptance of both strategies for case finding of survivors of ovarian cancer in primary care for GCT is promising, but larger studies are required before wide-scale implementation is warranted
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys
Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most neglected tropical diseases based on limited availability of drugs that are safe and efficacious, particularly against the second stage (central nervous system [CNS]) of infection. In response to this largely unmet need for new treatments, the Consortium for Parasitic Drug Development developed novel parenteral diamidines and corresponding oral prodrugs that have shown cure of a murine model of second stage HAT. As a rationale for selection of one of these compounds for further development, the pharmacokinetics and efficacy of intramuscular (IM) active diamidine 2,5-bis(5-amidino-2-pyridyl)furan (DB829; CPD-0802) and oral prodrug2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868) were compared in the vervet monkey model of second stage HAT. Treatment was initiated 28 days post-infection of monkeys with T. b. rhodesiense KETRI 2537. Results showed that IM DB829 at 5 mg/kg/day for 5 consecutive days, 5 mg/kg/day every other day for 5 doses, or 2.5 mg/kg/day for 5 consecutive days cured all monkeys (5/5). Oral DB868 was less successful, with no cures (0/2) at 3 mg/kg/day for 10 days and cure rates of 1/4 at 10 mg/kg/day for 10 days and 20 mg/kg/day for 10 days; in total, only 2/10 monkeys were cured with DB868 dose regimens. The geometric mean plasma Cmax of IM DB829 at 5 mg/kg following the last of 5 doses was 25-fold greater than that after 10 daily oral doses of DB868 at 20 mg/kg. These data suggest that the active diamidine DB829, administered IM, should be considered for further development as a potential new treatment for second stage HAT
Primary and relapse parasitaemia in infected vervet monkeys treated with the diamidine prodrug DB868.
<p>DB868 was administered orally at (<b>A</b>) 20 mg/kg/day, (<b>B</b>) 10 mg/kg/day, or (<b>C</b>) 3 mg/kg/day for 10 consecutive days following infection with <i>T. b. rhodesiense</i> KETRI 2537 (28–37 days post-infection); the monkeys were confirmed to have progressed to second stage HAT before initiation of treatment. Relapse infections occurred at different times in specific individuals. Relapsed monkeys were rescue-treated with melarsoprol administered intravenously at 3.6 mg/kg/day for 4 consecutive days. F, female; M, male.</p
Resolution of parasitaemia in infected vervet monkeys treated with the active diamidine DB829.
<p>Monkeys were infected with <i>T. b. rhodesiense</i> KETRI 2537 and later confirmed to have progressed to second stage HAT, were administered with DB829 intramuscularly at (<b>A</b>) 5 mg/kg/day for 5 consecutive days (28–32 days post-infection), (<b>B</b>) 5 mg/kg/day for 5 alternate days (28, 30, 32, 34 and 36 days post-infection), or (<b>C</b>) 2.5 mg/kg/day for 5 consecutive days (28–32 days post-infection). F, female; M, male.</p
Parasitaemia progression in vervet monkeys following infection.
<p>Monkeys were infected with <i>T. b. rhodesiense</i> KETRI 2537 on Day 0. Symbols represent means and standard error of the mean (n = 16).</p
Structures of active diamidines and corresponding prodrugs.
<p>Structures of active diamidines and corresponding prodrugs.</p
Plasma concentration-time profiles of DB829 following administration of the diamidine prodrug DB868 to infected vervet monkeys.
<p>Monkeys confirmed to have second stage HAT were administered DB868 orally, beginning at 28 days post-infection with <i>T. b. rhodesiense</i> KETRI 2537, at 20, 10 or 3 mg/kg/day for 10 consecutive days. The inset graph shows the extended profile out to the end of the study. * denotes the time that monkey 670 (1 day post-last drug dose), monkey 687 (82 days post-last drug dose) and monkey 696 (130 days post-last drug dose) were euthanized due to clinical morbidity. F, female; M, male.</p